The Falsified Medicines Directive: Five steps to compliance

25 January 2019

Ahead of the Falsified Medicines Directive (FMD) coming into play in the European Union on February 9, Christian Taylor, Serialization Business Consultant at Zetes, provides his five-step plan to becoming FMD compliant in an Expert View piece.

The FMD 2011/62/EU aims to increase the security of the manufacturing process and delivery of medicines throughout Europe, providing greater protection for patients.

Organizations that have not yet become compliant must now act fast to ensure they don’t fall foul of the regulation. So, what can be done to make sure FMD compliance projects are completed in time and that the chosen solutions are robust enough to guarantee immediate compliance? This is a five-step plan to becoming FMD compliant:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK